Regulatory Filings • May 30, 2022
Regulatory Filings
Open in ViewerOpens in native device viewer
Lyon (France), May 30, 2022 - 17h45 - AMOÉBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and of a biocontrol product for plant protection, still in development phase, updates the regulatory calendar for both the biocide and biocontrol applications in the US.
The application for approval of the biocidal active substance, the living amoeba Willaertia magna C2c Maky, and biocidal products containing it, filed in April 2021 with the U.S. Environmental Protection Agency (U.S. EPA), is still under review. The conclusions were, according to the legal deadline announced by the authority, expected by mid-2022. The U.S. EPA has requested an extension of the assessment period: the conclusions of the assessment should now be available in the second half of 2022.
The application for approval of the biocontrol active substance, the lysate of Willaertia magna C2c Maky, and the biocontrol products containing it, filed in October 2020 with the U.S. Environmental Protection Agency (EPA), is still under review. The conclusions were, according to the legal deadline announced by the authority, expected by the end of May 2022. The U.S. EPA has requested an extension of the assessment period: the conclusions of the assessment should now be available in the second half of 2022.
Amoéba's ambition is to become the world leader in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection estimated globally at €1.6Bn (3). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (4) in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The company is currently in the testing phase for biocidal and phytosanitary applications and does not market any products.
Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-nature.com.
(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
Contacts: Amoéba Valérie FILIATRE Deputy General Manager +33 4 26 69 16 00 [email protected]
Calyptus Investor & Press Relations Nicolas HELIN / Mathieu CALLEUX +33 1 53 65 37 90 /91 [email protected]
This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 12, 2022 under number D22-0280 and available on the AMOÉBA website (www.amoeba-nature.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forwardlooking statements.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.